Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada

AIM: The costs and consequences of initial and delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease in Canada. MATERIALS & METHODS: A Markov cohort model was used (10-year horizon, annual cycle length, 1.5% discounting). Scenario analyses exam...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhan, Virender, Clift, Fraser, Baharnoori, Moogeh, Thomas, Kimberly, Patel, Barkha P, Blanchette, François, Adlard, Nicholas, Vudumula, Umakanth, Gudala, Kapil, Dutta, Nikkita, Grima, Daniel, Mouallif, Soukaïna, Farhane, Fatine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690431/
https://www.ncbi.nlm.nih.gov/pubmed/37606897
http://dx.doi.org/10.57264/cer-2022-0175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690431/
https://www.ncbi.nlm.nih.gov/pubmed/37606897
http://dx.doi.org/10.57264/cer-2022-0175

Ejemplares similares